Eli Lilly Reports Record Q3 Earnings Driven by Zepbound and Mounjaro Demand

Eli Lilly & Co. today announced third-quarter earnings and revenue that exceeded expectations, fueled by continued strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro, signaling a significant shift in the pharmaceutical landscape.

The pharmaceutical giant reported revenue of $17.60 billion for the quarter, a 54% increase year-over-year, and raised its full-year revenue guidance to between $63 billion and $63.5 billion. Mounjaro generated $6.52 billion in revenue, a 109% increase from the same period last year, while Zepbound brought in $3.57 billion, up 184%. Adjusted earnings per share reached $7.02, surpassing the expected $5.69. This financial performance underscores the growing demand for GLP-1 receptor agonists, a class of drugs transforming the treatment of obesity and diabetes.

The company’s success is partially attributed to increased volume – a 60% jump in prescriptions and units sold – though partially offset by lower realized prices. Eli Lilly has also focused on expanding access to Zepbound, recently partnering with Walmart to offer discounted in-store pickup for cash-paying patients. The competitive landscape is heating up, as evidenced by Novo Nordisk’s rival bid for U.S. obesity biotech company Metsera, attempting to challenge Eli Lilly’s dominance in the GLP-1 market; you can learn more about GLP-1 medications on the FDA website.

Eli Lilly officials stated the current guidance does not include potential impacts from recently threatened tariffs on pharmaceutical imports into the U.S. The company is also anticipating the potential of its experimental obesity pill, orforglipron, to further solidify its position in the market.